Healthcare firm Abbott has secured approval from the US Food and Drug Administration (FDA) for its FreeStyle Libre Pro continuous glucose monitoring (CGM) system.

The company has developed the new system for healthcare professionals to offer better diabetes management for patients.

FreeStyle Libre Pro system provides visual snapshot of glucose data called ambulatory glucose profile (AGP). It offers clear overview of glucose levels, as well as patterns and trends within those levels.

Healthcare professionals will apply the system to patients in a clinic setting. He will place a small and round sensor on the back of the patient's upper arm.

The water-resistant and disposable sensor, which can remain on the back of the arm for up to 14 days, will continuously measure glucose in interstitial fluid through a small filament that is inserted just under the skin.

The sensor will record glucose levels at every 15 minutes, helping to get 1340 glucose results in around 14 days. It provides doctors with comprehensive data related to glycemic profile of the patient.

After 14 days, the doctor will use FreeStyle Libre Pro reader to scan the sensor and download the glucose results that are stored in the sensor.

Abbott diabetes care senior vice president Jared Watkin said: "FreeStyle Libre Pro transforms how doctors assess their patients' diabetes.

"This novel technology provides a solution to the ongoing challenge of the need for complete and dependable glucose data. This data is imperative for not only the doctor, but also for the patient to help them achieve optimal health."